EGFR and neoplasm: Therefore, in the present study, we have evaluated whether enzastaurin is able to inhibit the growth in vitro and in nude mice of a variety of human tumours with different degree of expression of EGFR and PKCβ, including those with acquired or spontaneous resistance to the EGFR inhibitor gefitinib, correlating the effect with the expression of proteins involved in the acquisition of resistance to anti-EGFR drugs.